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ABSTRACT
Weight, weight gain, and obesity account for approx-
imately 20% of all cancer cases. Evidence on the re-
lation of each to cancer is summarized, including
esophageal, thyroid, colon, renal, liver, melanoma,
multiple myeloma, rectum, gallbladder, leukemia,
lymphoma,andprostateinmen;andpostmenopausal
breast and endometrium in women. Different mecha-
nisms drive etiologic pathways for these cancers.
Weight loss, particularly among postmenopausal
women,reducesriskforbreastcancer.Amongcancer
patients, data are less robust, but we note a long his-
tory of poor outcomes after breast cancer among
obese women. While evidence on obesity and out-
comes for other cancers is mixed, growing evidence
points to benefits of physical activity for breast and
colon cancers. Dosing of chemotherapy and radiation
therapyamongobesepatientsisdiscussedandtheim-
pact on therapy-related toxicity is noted. Guidelines
for counseling patients for weight loss and increased
physical activity are presented and supported by
strong evidence that increased physical activity leads
to improved quality of life among cancer survivors.
The “Five A’s” model guides clinicians through a
counseling session: assess, advise, agree, assist, ar-
range. The burden of obesity on society continues to
increase and warrants closer attention by clinicians
for both cancer prevention and improved outcomes
after diagnosis. The Oncologist 2010;15:556–565
INTRODUCTION
Because weight, weight gain, and strategies to manage
weightareimportantbothfortheriskfordevelopingcancer
and for survival among cancer patients, we divided this re-
view into two sections relating to the patient population.
We then present a set of strategies that can be useful to
guide clinical advice to patients for whom weight control is
an important adjunct to risk management or to improve
quality of life and disease-free survival after diagnosis.
WEIGHT,W EIGHT GAIN, AND RISK FOR CANCER
Althoughevidenceshowsthatadultoverweightandobesity
are related to risk for many cancers, the growing epidemic
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The Oncologist 2010;15:556–565 www.TheOncologist.comof obesity provides a challenge to clinical practice and the
implementation of guidelines for the management of
weight. Historical data from the past 25 years point to obe-
sity as a cause of approximately 14% of cancer deaths in
men and up to 20% of cancer deaths in women [1]. These
may be conservative estimates because the population has
gained substantial weight over this time period and the
prevalence of overweight and obesity has increased from
15% in 1980 to 35% in 2005 [2] (Fig. 1). Some now esti-
mate that the total health burden of overweight and obesity
may exceed that for cigarette smoking [3].
Amajorreviewofweight,physicalactivity,andcancerin-
cidence by the International Agency for Research on Cancer
(IARC)usedobesityprevalencedatafromEuropeandrelative
risksfromameta-analysisofpublishedstudiesandconcluded,
in2002,thatobesitywasacauseof11%ofcoloncancercases,
9% of postmenopausal breast cancer cases, 39% of endome-
trial cancer cases, 25% of kidney cancer cases, and 37% of
esophageal cancer cases [4]. In addition, data from the Amer-
ican Cancer Society suggested that overweight and obesity
were related to mortality from liver cancer, pancreatic cancer,
non-Hodgkin’s lymphoma, and myeloma [1]. This effect on
mortalityreflectsboththeexcessincidenceandexcessmortal-
ityamongthosewithcancer.Sincethe2002IARCreport,sub-
stantial new evidence has supported a cause-and-effect
relationbetweenoverweightandobesityandtheonsetofthese
cancers,furtherincreasingtheburdenofcancerresultingfrom
obesity [5]. The American Institute for Cancer Research and
WorldCancerResearchFundreportedthatthereisconvincing
evidence for a relation between obesity and esophageal, pan-
creatic, colorectal, postmenopausal breast, endometrial, and
kidneycancers,withprobableevidenceforgallbladdercancer.
In addition, they found probable evidence that abdominal fat-
ness, in particular, increases the risk for pancreatic, endome-
trial, and postmenopausal breast cancer. Finally, emerging
evidence suggests that obesity increases risk for aggressive
prostate cancer [6]. Overall, we estimate that overweight and
obesity cause approximately 20% of all cancer cases. Previ-
ously Doll and Peto [7] included overnutrition (overweight)
with diet causing a combined 35% of all cancer cases. In Fig-
ure 2, we break out overweight and obesity from diet and pro-
vide updated estimates for the causes of cancer.
To conclude that a cause-and-effect relation exists be-
tween obesity and cancer at each site, one often pursues
studies of mechanisms that confirm the underlying biology
of this relation and provide insights into prevention strate-
gies. Take, for example, postmenopausal breast cancer.
Among postmenopausal women, obesity is directly related
to circulating estradiol levels [8], which themselves are di-
rectly related to breast cancer risk [9, 10]. When the action
of estrogens is interrupted by estrogen receptor modulators
in randomized controlled trials, breast cancer incidence is
approximately 50% lower [11, 12].
Justassmokingcessationleadstoareductionintheriskfor
lung cancer, adding to the evidence of a cause-and-effect rela-
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Figure 1. Trends in obesity, U.S.
Abbreviation: BMI, body mass index.
Source: NCHS 2008. Available at http://www.cdc.gov/nchs/data/hestat/overweight/overweight_adult.htm.
Figure 2. Estimated proportion of cancer in the U.S. that
could have been avoided by changes in each category of non-
genetic cancer causes.
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among women who lost 10 kg after menopause and kept it
off [13] adds to our understanding of this causal relation. In
addition, focusing on weight loss after menopause, a time in
life when obesity clearly increases the risk for breast cancer,
provides important evidence on the time frame for change in
cause (weight) and subsequent change in cancer incidence.
Thislowerincidenceofpostmenopausalbreastcancerfollows
the decline in circulating estrogen after weight loss.
For colon cancer, growing evidence points to insulin
pathwaysmediatingtheeffectofbodymassindexBMIand
risk [14]. Studies of blood glucose levels and colon cancer
show a direct relation between higher glucose and subse-
quent risk [14]. Providing further biologic rationale, c-
peptide[15],amarkerofinsulinproduction,alsoshowsthis
positive relation, and animal models using insulin injection
versussalineshowasignificantlyhigherincidenceofcolon
cancer among those injected with insulin [16]. Finally, pre-
clinical data provide additional support for the insulin–
insulin-like growth factor (IGF) hypothesis of cancer risk,
as outlined in several excellently detailed recent reviews
[17,18].Thephosphoinositide3-kinase/Aktpathwaylikely
compromises the downstream target of insulin, and is one
ofthepathwaysmostcommonlyalteredinepithelialtumors
[18, 19]. In sum, strong evidence points to hyperinsulin-
emia as the direct pathway from adiposity to colon cancer.
For each cancer site, we present summary estimates of rel-
ativeriskfromtherigorousmeta-analysisbyRenehanetal.
[5] and the likely pathway or mechanism for a causal rela-
tion between obesity and cancer (Tables 1 and 2).
Of particular importance is the rapid rise in adenocarci-
noma of the esophagus over the past 20 years. In parallel
with the global epidemic of obesity, the morphology of
esophageal cancer has shifted from squamous to adenocar-
cinoma,andagrowingbodyofresearchpointstotheroleof
obesityinesophagealreflux,apathwayforthismalignancy
[20]. Increasing BMI in the Nurses’ Health Study was as-
sociatedwithasignificantlyhigherriskforrefluxesophagi-
tis [21]. Weight gain was associated with a higher risk for
developing frequent reflux, and a weight loss of 3.5 kg was
associated with a significantly lower risk for frequent
symptomsofgastroesophagealrefluxdisease[21].Therole
of weight loss and the time course of the lower risk for
esophageal cancer remain to be documented.
Mechanisms Differ
One concern raised by some is that obesity cannot cause
cancer through so many different mechanisms. This opin-
Table 1. RR for cancer per 5 kg/m
2 higher BMI and most likely causal mechanism: Males
Cancer type RR Causal mechanism
Esophageal adenocarcinoma 1.52
a Reflux esophagitis and chronic irritation
Thyroid 1.33
c Unknown
Colon 1.24
a Insulin
Renal 1.24
a In part though hypertension
Liver 1.24 Fatty liver cirrhosis
Malignant melanoma 1.17
b ?
Multiple myeloma 1.11
a Inflammatory pathways—IL-6
Rectum 1.09
a ?
Gallbladder 1.09 Chronic secretion-gallstones and irritation
Leukemia 1.08
b ?
Pancreas 1.07 Possible insulin pathway
Non-Hodgkin’s lymphoma 1.06
a Inflammatory pathways—IL-6
Prostate
a 1.03 ?
Lung 0.76
a Smoking leads to leanness and causes lung cancer
Esophageal squamous 0.71
a Smoking leads to leanness and causes squamous esophageal cancer
Shown is the RR for a five-point greater BMI—for example, the RR linked to a BMI of 28 compared with a BMI of 23, or a
BMI of 32 compared with a BMI of 27.
ap  .0001.
bp  .01.
cp  .05.
dBiased to null because this includes predominantly low-grade lesions.
Abbreviations: BMI, body mass index; IL, interleukin; RR, relative risk.
Based on Figure 3 of Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: A systematic review
and meta-analysis of prospective observational studies. Lancet 2008;371:569–578.
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known to differ for different organ sites. Female hormones
causebreastandendometrialcancerbuthavemuchlessim-
pact on other cancers, for example. Insulin may drive colon
and prostate cancer [22] (Fig. 3), whereas inflammation
may drive other malignancies. All these mechanisms can
have a role in mediating the relation between obesity and
cancer risk. As noted by Roberts et al. [17], in their review
of the biologic mechanisms linking obesity and cancer risk,
the pathophysiology of obesity is complex and multisys-
temic, and thus, it is unlikely that “one size fits all.”
WEIGHT LOSS AND CANCER RISK REDUCTION
Despite extensive evidence showing a deleterious effect of
overweight and obesity on cancer, relatively few data exist
on the effects of weight gain or weight loss on altering the
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Figure 3. Serum insulin and risk for prostate cancer. p (trend)  .02.
Based on Table 3 of Albanes D, Weinstein SJ, Wright ME et al. Serum insulin, glucose, indices of insulin resistance, and risk
of prostate cancer. J Natl Cancer Inst 2009;101:1272–1279.
Table 2. RR for cancer per 5 kg/m
2 higher BMI and most likely causal mechanism: Females
Cancer type RR Causal mechanism
Endometrium 1.59
a Endogenous estrogen
Gallbladder 1.59
c Chronic secretion-gallstones and irritation
Esophageal adenocarcinoma 1.51
a Reflux esophagitis and chronic irritation
Renal 1.34
a In part through hypertension
Leukemia 1.17
c Unknown
Thyroid 1.14
b Unknown
Breast (postmenopausal) 1.12
c Endogenous estrogen
Pancreas 1.12
c Possible insulin pathway
Multiple myeloma 1.11
a Inflammatory pathways—IL-6
Colon 1.09
a Insulin
Non-Hodgkin’s lymphoma 1.07 Inflammatory pathways—IL-6
Liver 1.07 Fatty liver cirrhosis
Breast (premenopausal) 0.92
b Irregular menstrual cycles, hormones
Lung 0.8
c Smoking leads to leanness and causes lung cancer
Esophageal squamous 0.57
a Smoking leads to leanness and causes squamous esophageal cancer
RR for a five-point greater BMI—for example, the RR linked to a BMI of 28 compared with a BMI of 23, or a BMI of 32
compared with a BMI of 27.
ap  .0001.
bp  .01.
cp  .05.
Abbreviations: BMI, body mass index; IL, interleukin; RR, relative risk.
Based on Figure 4 of Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: A systematic review
and meta-analysis of prospective observational studies. Lancet 2008;371:569–578.
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function of the small number of individuals able to achieve
a sustained weight loss.
The IARC evaluated data through 2000 and found lim-
itedevidenceforanassociationbetweenweightchangeand
the risk for colorectal cancer [4]. However, subsequent
studies have added evidence to support this adverse effect.
Cohort studies examined changes in weight from early
adulthoodtolaterinlifeandfoundmodestlyhigherrelative
risks (1.4–1.6). Case–control studies provided additional
support. More recent evidence confirms that weight gain in
adulthood appears to increase the risk for colon cancer. In a
case–control study in Canada, men who gained 21 kg af-
ter the age of 20 had a 60% higher risk for colorectal cancer
than men who had gained 1–5 kg [23]. The association was
strongerwhenrectaltumorswereexcluded,suggestingthat
studies that examine the association between weight gain
andcolorectalcancermayunderestimatetheassociationfor
coloncancer.Noassociationbetweenweightgainandcolo-
rectal cancer risk was observed among women, for whom
higher estrogen levels may counter the adverse effect of
obesity through insulin pathways. Another study of men
and women found that, compared with those whose BMI
had remained stable, those whose BMI had increased from
age 30 or 50 to diagnosis had a 25%–35% higher risk for
colorectal cancer [24]. Finally, a study of Austrian adults
foundevidenceforadirectassociationbetweenweightloss
and a reduction in colon cancer risk among men [25].
Perhaps the best evidence that weight loss can reduce
the risk for cancer comes from recent studies in bariatric
surgery patients. Emerging evidence from two large cohort
studies suggests that large weight loss from bariatric sur-
gery reduces the risk for cancer death [26, 27]. The mean
weightlosswasintherangeof14%–27%15yearsaftersur-
gery in the Swedish patient population [27]. In the U.S. pa-
tient sample, cancer death rates, excluding prevalent
cancers, were 38% lower (hazard ratio [HR], 0.62; 95%
confidenceinterval[CI],0.61–0.74)inpatientsundergoing
Roux-en-Y gastric bypass than in BMI-matched controls,
withsomeindicationthatthereductioninthedeathratewas
stronger in men than in women [26]. The cancer death rate
reductionwaslargerwhenincludingprevalentcasesofcan-
cer at baseline (HR, 0.40; 95% CI, 0.25–0.65). The limited
sample sizes in both studies precluded examination of can-
cer-specific rates, though Sjöström and colleagues noted
that the results included both deaths from obesity-related
cancers and deaths from cancers unrelated to obesity [27].
Morerecently,bothstudiesdemonstratedalowercancerin-
cidence in surgical patients. The Swedish study demon-
strated a lower risk for cancer in women undergoing
bariatric surgery than matched obese controls (HR, 0.58;
95%CI,0.44–0.77),thoughnosucheffectwasobservedin
men (HR, 0.97; 95% CI, 0.62–1.52) [28]. The amount of
weight loss was not associated with cancer risk. Similarly,
the U.S.-based study found a significant cancer risk reduc-
tion in bariatric surgery patients (HR, 0.76; 95% CI, 0.65–
0.89). That study found that this risk reduction was largely
concentratedinobesity-relatedcancers(i.e.,esophagealad-
enocarcinoma, colorectal cancer, pancreatic cancer, post-
menopausal breast cancer, corpus and uterus cancers,
kidney cancer, non-Hodgkin’s lymphoma, leukemia, mul-
tiple myeloma, liver cancer, and gallbladder cancer). Sub-
sequentstudieshavereportedsimilarcancerriskreductions
[29, 30].
Ample observational data support a detrimental effect
of obesity on the risk for several cancers, including breast
andcoloncancer,twoofthemostcommoncancersinNorth
America and Europe. Examination of possible mechanisms
provides further evidence that the observed associations
havebiologicrationale.Finally,growingresearchindicates
that a change in weight is associated with subsequent
changes in the risk for several cancers. Weight loss after
menopause significantly reduces the risk for breast cancer
[13]. Taken together, this indicates an important role for
obesity and weight change in cancer risk.
IMPACT OF OBESITY AMONG CANCER PATIENTS
Far fewer studies address weight or weight change and sur-
vival following a cancer diagnosis. A long-standing associ-
ation between obesity and poor outcomes for women with
breast cancer [31, 32] has received increasing attention
[33].Themajorityofevidencepointstoweightatdiagnosis
as the major lifestyle risk for poor breast cancer outcomes
(andpoorerqualityoflife)[34],withgrowingevidencethat
weight gain after diagnosis exacerbates risk [33]—a result
seen most clearly among women who were lean at diagno-
sis or nonsmokers. Nonsmoking women who gained 2
kg/m
2 after a breast cancer diagnosis had a relative risk for
death during 9 years of follow-up that was 1.64 (95% CI,
1.07–2.51), compared with stable weight women (Fig. 4).
Insulin pathways have been suggested as one mechanism
forthiseffect[35].Weightgainfollowingdiagnosismaybe
particularly problematic because research suggests that it is
largely an increase in fat mass and not muscle mass [36].
Furthermore,evidencethatphysicalactivityafterdiagnosis
reduces the risk for breast cancer recurrence [37] and inter-
vention trials of diet and physical activity that showed
longer disease-free survival times among the intervention
group,themembersofwhichlostsubstantiallymoreweight
than the control group [38], all point to the importance of
energy balance after breast cancer.
Although obesity is not associated with prostate cancer
560 Obesity and Cancerincidence overall, it is associated with fatal and aggressive
disease [6]. There is also emerging evidence that prostate
cancer is more difficult to detect in obese men [6]. Obese
men have a higher risk for recurrence following prostatec-
tomy [6, 39, 40], but there is no evidence for higher rates of
recurrenceamongobesemenundergoingbrachytherapy[6,
39, 41]. Obese men also have higher rates of death from
prostate cancer [6]. However, some reports suggest that
obese patients with metastatic prostate cancer may have
better postdiagnosis outcomes, perhaps because obesity
acts as a cachexia preventive [42].
Evidence for an effect of obesity on colon cancer sur-
vival is mixed. Meyerhardt et al. [43] found no association
with disease-free survival time or overall mortality (pa-
tients all received weight-based treatment, so this could not
be attributed to chemotherapy underdosing). Subsequent
reports have indicated that those who are very obese (class
2 obesity) have greater overall mortality and shorter dis-
ease-free survival intervals [44–46]. However, the one
study to look at the effects of weight change found no as-
sociation with survival outcomes [44]. In addition, in one
study [45], chemotherapy dose was capped for the very
obese, which may confound the findings. The implications
of worse outcomes for the morbidly obese are particularly
worrisome because this is a rapidly increasing segment of
the population.
Inadditiontotheimpactofobesityondiseaseincidence
and progression, concern has been raised regarding the po-
tential for dosing of therapy to be poorly matched to weight
inheaviercancerpatients.Thenarrowtherapeuticindexas-
sociated with many chemotherapeutic drugs prompts a ra-
tional concern on the part of the medical oncologist that the
highdosesofchemotherapyrequiredbytheveryobesewill
resultinexcesstoxicity.Researchinthisareahassuggested
that obese patients are frequently treated at lower chemo-
therapy dose intensities than the nonobese. Paradoxically,
studies have not demonstrated greater chemotherapy-re-
latedtoxicityinobesepatientstreatedatfulldoseintensities
[47]. This refutes the notion that obese patients should uni-
formly receive dose-reduced therapy. For obese patients
being treated with curative intent, dose reductions should
be approached with particular caution.
Asimilarproblemwithregardtochemotherapyinobese
patients surrounds the common use of body surface area
(BSA) for dose calculation. Historically, cytotoxic chemo-
therapeutic agents have been dosed this way based on the
assumption that metabolism is proportional to BSA, a the-
ory first described by Rubner in 1883. One of the more
commonly used formulae is based on measurements per-
formed on a small number of individuals, reported nearly
100 years ago [48]. Although the BSA approach may be
helpful when extrapolating doses between mice and hu-
mansduringthetranslationalperiodfrompreclinicaltoear-
ly-phase clinical studies, some have questioned whether
thisapproachisappropriateinclinicalpractice[49].Forex-
ample, a man who is 180-cm tall with an ideal body weight
of71kghasaBSAof1.9,accordingtotheDuboisformula,
whereas another man who is 180-cm tall and who weighs
twice as much (142 kg) has a BSA of 2.55. The BSA in the
lattermanis34%greaterthantheBSAinthemanwithideal
body weight, whereas the weight of the latter man is 100%
greater. Particularly for drugs with any degree of fat solu-
bility (higher volume of distribution), BSA dosing is likely
to result in systematic underdosing, compared with weight-
based dosing. With increasing attention being paid to che-
motherapy dose intensity as a predictor of treatment
response in numerous tumor types, careful reconsideration
of the optimal dosing in obese patients may be appropriate
for some drugs [47, 50].
Obesity may also interfere with the ability to deliver
other forms of treatment. Wong et al. [51] found that there
was a shift in the delivery of external-beam radiation in
obese patients, resulting in the target location not receiving
the full dose. In addition, research has suggested that,
Figure 4. Sustained weight loss and breast cancer risk in postmenopausal women who never used postmenopausal hormones.
Based on Table 3 of Eliassen AH, Colditz G, Rosner B et al. Adult weight change and risk of postmenopausal breast cancer.
JAMA 2006;296:193–201.
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may not be as clean in obese men and they may have fewer
nerve bundles preserved [52].
Quality of life among cancer patients and those free
from cancer is reduced by higher BMI. Limited data sug-
gest that weight loss is associated with improved quality of
life. More substantial data point to an increase in physical
activity among cancer survivors leading to significant in-
creases in quality of life [53].
Mechanisms
Among cancer survivors, the likely pathways from obesity
leading to recurrence and death again may vary by tumor
site. Insulin receptors are increasingly being studied as a
mechanism for obesity to have adverse effects among
breast cancer survivors. The insulin receptor is overex-
pressed and may bind both insulin and IGF-II [54]. Among
colon cancer patients, the insulin pathway has again been
identified as potentially mediating adverse outcomes, and
recent research addressing obesity and STMN1 (stathmin
or oncoprotein-18), which destabilizes microtubules and
reorganizes cytoskeleton and functions in cell progression
and cell migration, indicates that the adverse effect of BMI
among colon cancer patients may be limited to those who
are STMN1
 [55].
Metformin is associated with a lower cancer incidence
among diabetics [56] and with lower cancer mortality
among patients with type 2 diabetes [57]. Among mecha-
nisms for such a benefit are the inhibition of cancer cell
growth, suppression of ErbB-2 oncoprotein overexpres-
sion, and inhibition of mammalian target of rapamycin
[58–60].Thisrapidlyexpandingareaoflaboratoryandhu-
manevidencepointstoaroleformetforminamongdiabetic
patients, with clinical trials now proposed [61].
Inflammation is also a source of great interest. Adipo-
cytesreleaseinflammatorymarkers,whichareincreasingly
being found to be associated with a worse postdiagnosis
prognosis. In the Healthy Eating, Activity, and Living
(HEAL) study, serum amyloid a and c-reactive protein lev-
els were associated with shorter overall survival in breast
cancer patients [62]. As with the hypothesized mechanisms
linking obesity to cancer risk, ample preclinical data detail
the linkages in these pathways [17, 18].
WEIGHT LOSS AND INTERMEDIATE ENDPOINTS
Many randomized controlled trials of weight loss and mea-
sures of insulin, glucose, and blood pressure show a strong
response to an increase in activity and a reduction in adi-
posity[63].Lackofenergyexpenditureintheformofphys-
ical activity is a leading determinant of higher body mass.
For those who are already overweight, physical activity, in
combination with dietary changes, is important for achiev-
ing, and particularly for maintaining, weight loss [63].
There is increasing evidence [64] that attaining 9,000
daily steps as an indicator of physical activity is associated
with a lower likelihood of being obese, including among
lower income and racial/ethnic minority populations. TV
viewingisahighlyprevalentsedentaryactivity;Americans
watchatleast4hoursofTVeachdayandTVviewingisthe
most prevalent activity after work and sleep. TV viewing is
positively associated with excess body weight among chil-
dren and adults [65, 66]. TV viewing may also promote
obesity through the promotion of consumption of calori-
cally dense foods through advertising and other media con-
tent[67].ThestrongandconsistentassociationbetweenTV
viewing and obesity suggests the importance of including
reduction in TV hours as a target in behavioral weight re-
duction efforts.
BENEFITS OF WEIGHT LOSS AND INCREASED
PHYSICAL ACTIVITY AMONG CANCER SURVIVORS
Strong evidence supports the idea that an increase in phys-
ical activity leads to improved quality of life among cancer
survivors [53]. Among men after prostate surgery, being
leanandphysicallyactiveisassociatedwithsuperiorsymp-
toms of incontinence, compared with obese and inactive
men, suggesting a role for weight loss after prostate resec-
tion to improve quality of life [68].
The National Heart, Lung and Blood Institute evidence
review on weight loss [63] evaluated 86 randomized, con-
trolled trials and concluded that “low calorie diets are rec-
ommended for weight loss in overweight and obese
persons” (evidence category A) and that “Physical activity
is recommended as part of a comprehensive weight loss
therapy and weight control program because it modestly
contributes to weight loss” (evidence category A) [63].
Specific recommended intake levels vary based on a num-
ber of factors, including current weight, activity levels, and
weight loss goals. There are many other behavioral factors
that influence weight loss and may be more effectively in-
tervened upon over an extended intervention period to
achieve sustained weight loss. We outline several of these
in Figure 5. Rather than focus on specific calorie calcula-
tions, we recommend behavioral targets that should lead to
an energy deficit as well as increase and maintain patient
motivation.
COUNSELING FOR WEIGHT LOSS
Providers play a central role in guiding their patients to fol-
low strategies to reduce or maintain their weight and thus
improve their quality of life and reduce their risk for devel-
oping a primary malignancy, or improve survival among
562 Obesity and Cancerthose diagnosed with cancer. Given the prevalence of over-
weight and obesity, weight loss is a sound strategy for re-
ducing the risk for cancer. Here, we briefly outline
strategies that a provider can use to counsel patients to
maintain weight and achieve a sustained weight loss.
For effective weight change interventions, one would
like to have on hand strategies to address individual behav-
iors, social factors that might reinforce individual behavior
change, and environmental strategies (such as safe side-
walks and effective transportation systems, etc.) [69] that
promote or discourage a given behavior.
The Diabetes Prevention Trial demonstrated the effi-
cacy of an intensive health care provider–based interven-
tion to reduce weight and increase physical activity over a
24-month period and thereby prevent diabetes [70]. Trans-
lating this efficacy study into effective approaches that
work in the broader clinical setting remains to be demon-
strated. One approach, derived from the methodology orig-
inally developed by the National Cancer Institute to guide
physicians in counseling their patients to quit smoking, the
“Five As” model guides clinicians through a counseling
session, with each “A” corresponding to a brief behavioral
intervention—assess, advise, agree, assist, arrange —
which together have been shown to be effective. Clinicians
may use the Five As approach to deliver behavior change
strategy messages (such as those in Fig. 5).
Interactive technologies can also address a wide variety
of health behavior domains simultaneously. Thus, interac-
tive technology can provide a streamlined, consistent
method for conducting many aspects of evidence-based be-
havior change counseling, including assessing current
health behaviors, identifying barriers to change, allowing
the patient to set goals and select relevant activities, and ar-
ranging follow-up support.
Evidence from randomized trials demonstrates that the
use of interactive technologies supports lifestyle behavior
change [71], although most of this research was conducted
using a single-disease and/or single behavior change focus.
Practice-based research indicates that clinicians who have
limitedfinancial,space,andpersonnelresourcesfavortools
that address comorbid conditions and health behaviors si-
multaneously.Inaddition,toolsthatcanbeaccessedviapa-
tients’ homes or from community settings are useful and
effective and appeal to clinicians who face barriers to pro-
viding self-management care tools [71].
Thus, there is great interest in the ability of interactive
and Web-based tools to deliver and reinforce behavior
change strategies in a cost-effective manner. Increasingly,
Web-based tools for supporting positive lifestyle changes
aremakingtheirwayintotheclinicalsetting.However,itis
unclear whether such interventions are effective. An in-
creasingnumberofstudiesarebeginningtoassesstheirpo-
tential to reduce weight, both in the health care setting and
beyond.
Summary of Provider Role
Because the factors that influence energy balance range
from the individual to the environment, efforts to shift the
population distribution of physical activity upward and diet
towardhealthierchoiceswillrequireemphasisonallthein-
tervention points: health care settings, communities, and
environment. The challenge for providers is to engage the
patient in understanding the importance of weight control
and increased physical activity to begin on the path to be-
havior change.
Safety Issues
Although the benefits of weight maintenance and greater
physical activity are well established for many chronic dis-
eases, the risks must also be considered. These include in-
juries, alteration in glucose control for diabetics, and
sustained increases in joint pain. In general, these risks are
outweighed by the vast benefits of weight loss and in-
creased physical activity and can generally be reduced with
simple steps. To date, drug-based strategies to aid with
weight loss have had side effects that reduce adherence.
CONCLUSION
Obesity causes a substantial proportion of all cancers, and
emerging evidence suggests that adult weight loss reduces
cancer risk. Increasing physical activity and avoiding
weight gain after cancer, as in adult life, have substantial
benefits.
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 Physical activity, diet, and behavioral goals for sustained weight loss.  
Physical Activity / Sedentary Behavior Goals 
1)  Brisk walking (or similar effort) for at least 20 minutes increasing up to 60 minutes, 6 
days per week OR walking a total of 10,000 steps per day (building up to 10,000 if 
needed) 
2)  Limit television to less than 2 hours per day. 
3)  Do strength training exercises at least 2 days per week 
Diet Goals  
1)  Replace sugary drinks with unsweetened choices (water, diet tea).  
2)  Eat breakfast every day.  
3)  Eat a diet rich in fruits and vegetables (8-10 svgs/d) and whole grain foods, like 
brown rice and whole wheat bread (at least 6 svgs/d).  
4)  Drink alcohol in moderation, if at all (no more than 1 drink/d for women, 2/d for men).   
Behavioral Goals 
1)  Log weight every day (at the same time every day) 
2)  Exercise at the same time every day (like before work/school; during lunch). 
3)  Keep portion sizes small and avoid seconds 
4)  Avoid fast food restaurants. Choose healthier options if you need to, like a salad with 
fat-free dressing or a fruit cup. 
Figure 5. Physical activity, diet, and behavioral goals for sus-
tained weight loss.
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